Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.9
4.9
Journals
Pharmaceutics
Special Issues
Recent Advances in Pulmonary Drug Delivery Systems
share announcement

Recent Advances in Pulmonary Drug Delivery Systems

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (20 January 2025) | Viewed by 6334

Special Issue Editors

Prof. Dr. Chuanbin Wu

E-Mail Website
Guest Editor
College of Pharmacy, Jinan University, Guangzhou 510632, China
Interests: soluble microneedle transdermal drug delivery technology; pulmonary drug delivery technology; long-acting injection microsphere technology; in-situ gel preparation technology; new antibacterial drug design and delivery technology; nano-targeted drug delivery technology
Dr. Xuejuan Zhang

E-Mail Website
Guest Editor
College of Pharmacy, Jinan University, Guangzhou 510632, China
Interests: pulmonary drug delivery system; industrial pharmacy; nasal drug delivery system
Dr. Sha Li

E-Mail Website
Guest Editor
College of Pharmacy, Jinan University, Guangzhou 510632, China
Interests: advanced drug delivery systems; generic drug development; extended and controlled release formulations

Special Issue Information

Dear Colleagues,

In recent years, pulmonary drug delivery systems have become a method of drug delivery that has attracted much attention. PDDSs refer to a special dosage form that is administered with a special device, such that a drug acts on the lungs and exerts local or systemic effects through the deep part of the respiratory tract. Pulmonary drug delivery systems have the advantages of being non-invasive, a quick onset, fewer local metabolic enzymes, and localized drug delivery, and are widely used in the treatment of respiratory diseases.

Despite several decades of research, the pulmonary delivery of biologics and high-dose active pharmaceutical ingredients, i.e., antibiotic, antibacterial, and antiviral drugs, is still challenging. There is still a significant gap between scientific research and clinical translation in enhancing lung deposition and bioavailability.

This Special Issue aims to collect the latest advances and state-of-the-art developments in the field of pulmonary drug delivery systems, including (but are not limited to) advanced drug delivery platforms for the treatment of respiratory diseases, in vitro/in silico/in vivo studies on the pulmonary drug delivery process and pulmonary deposition, the design of novel inhaler devices, studies relevant to potential lung toxicity and adverse effects of the excipients, and advanced delivery approaches for biopharmaceuticals. Notably, pulmonary drug delivery systems with high translational potential will be particularly preferred. Original research and review papers that reflect this topic’s status quo are warmly welcomed.

Prof. Dr. Chuanbin Wu
Dr. Xuejuan Zhang
Dr. Sha Li
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pulmonary drug delivery systems
  • dry powder inhalation
  • inhalation drug delivery
  • inhalation formulation and process development
  • design of novel inhaler devices
  • inhalation excipients
  • delivery processes of pulmonary drugs
  • inhalation nanoparticles
  • aerosol inhalation
  • pressurized metered-dose inhalation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 473 KiB  
Article
Optimization of Albuterol Delivery via Anesthesia Bag in Pediatric Critical Care
by Sébastien Tessier, Victoria K. Ploszay, Christian Robitaille, Jigneshkumar Vaghasiya, Andrew J. Halayko and Louise Chartrand
Pharmaceutics 2025, 17(2), 218; https://doi.org/10.3390/pharmaceutics17020218 - 8 Feb 2025
Viewed by 999
Abstract
Background/Objectives: Aerosolized medications are common practice for mechanically ventilated pediatric patients. Infants often receive nebulized medications via hand ventilation using an anesthesia bag, but evidence on optimal aerosol delivery with this method is limited. For this study, various configurations of the Mapleson breathing [...] Read more.
Background/Objectives: Aerosolized medications are common practice for mechanically ventilated pediatric patients. Infants often receive nebulized medications via hand ventilation using an anesthesia bag, but evidence on optimal aerosol delivery with this method is limited. For this study, various configurations of the Mapleson breathing circuit were tested to optimize albuterol delivery to a simulated pediatric model. Methods: Using a simulated pediatric lung model (ASL 5000) with the semi-open Mapleson anesthesia circuit, 2.5 mg/3 mL of albuterol sulfate solution was nebulized to a viral/bacterial filter (Respiguard 202). Four models were compared with varying fresh gas flows (FGFs), small-volume nebulizer (SVN) placements, and adjusting dead space. Five Registered Respiratory Therapists (RRTs) bagged the aerosol into a collection filter following defined ventilation parameters. Each model was tested in random order to avoid fatigue bias. Albuterol concentrations eluted from in-line filters were measured by spectrophotometry (absorbance at 276 nm). Results: No inter-user variability was observed among the RRTs. Significant differences in albuterol recovered were noted between models (One Way ANOVA, Tukey’s post hoc, n = 5). Model 4, with the nebulizer closest to the collecting filter, recovered 21.77 ± 1.89% of albuterol. The standard clinical model was the least effective, with only 0.10 ± 0.17% albuterol recovery. Conclusions: Modifying the anesthesia breathing circuit significantly improved aerosol drug delivery efficiency. Our findings suggest that current clinical practices for nebulized drug delivery are inefficient and can be markedly improved with simple adjustments in nebulizer positioning and gas flow within the circuit. Full article
(This article belongs to the Special Issue Recent Advances in Pulmonary Drug Delivery Systems)
►▼ Show Figures

Figure 1

Review

Jump to: Research

30 pages, 3155 KiB  
Review
Ciprofloxacin-Loaded Inhalable Formulations against Lower Respiratory Tract Infections: Challenges, Recent Advances, and Future Perspectives
by Vijay Kumar Panthi, Kathryn E. Fairfull-Smith and Nazrul Islam
Pharmaceutics 2024, 16(5), 648; https://doi.org/10.3390/pharmaceutics16050648 - 11 May 2024
Cited by 6 | Viewed by 3984
Abstract
Inhaled ciprofloxacin (CFX) has been investigated as a treatment for lower respiratory tract infections (LRTIs) associated with cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and bronchiectasis. The challenges in CFX effectiveness for LRTI treatment include poor aqueous solubility and therapy resistance. CFX [...] Read more.
Inhaled ciprofloxacin (CFX) has been investigated as a treatment for lower respiratory tract infections (LRTIs) associated with cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and bronchiectasis. The challenges in CFX effectiveness for LRTI treatment include poor aqueous solubility and therapy resistance. CFX dry powder for inhalation (DPI) formulations were well-tolerated, showing a remarkable decline in overall bacterial burden compared to a placebo in bronchiectasis patients. Recent research using an inhalable powder combining Pseudomonas phage PEV20 with CFX exhibited a substantial reduction in bacterial density in mouse lungs infected with clinical P. aeruginosa strains and reduced inflammation. Currently, studies suggest that elevated biosynthesis of fatty acids could serve as a potential biomarker for detecting CFX resistance in LRTIs. Furthermore, inhaled CFX has successfully addressed various challenges associated with traditional CFX, including the incapacity to eliminate the pathogen, the recurrence of colonization, and the development of resistance. However, further exploration is needed to address three key unresolved issues: identifying the right patient group, determining the optimal treatment duration, and accurately assessing the risk of antibiotic resistance, with additional multicenter randomized controlled trials suggested to tackle these challenges. Importantly, future investigations will focus on the effectiveness of CFX DPI in bronchiectasis and COPD, aiming to differentiate prognoses between these two conditions. This review underscores the importance of CFX inhalable formulations against LRTIs in preclinical and clinical sectors, their challenges, recent advancements, and future perspectives. Full article
(This article belongs to the Special Issue Recent Advances in Pulmonary Drug Delivery Systems)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop